public BRAFMutationAnalysisDetectedLynchSyndromeResult()
{
YellowstonePathology.Business.Test.IndicationLynchSymdrome indication = new IndicationLynchSymdrome();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Interpretation = "BRAF mutation detected.";
this.m_Method = YellowstonePathology.Business.Test.BRAFMutationAnalysis.BRAFMutationAnalysisResult.Method;
this.m_Comment = "The results are compatible with a sporadic tumor and further genetic evaluation is not indicated.";
this.m_References = YellowstonePathology.Business.Test.LynchSyndrome.LSERule.LSEColonReferences;
}
public BRAFV600EKDetectedLynchSyndromeResult()
{
YellowstonePathology.Business.Test.IndicationLynchSymdrome indication = new IndicationLynchSymdrome();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Interpretation = "BRAF mutation V600E detected.";
this.m_Method = YellowstonePathology.Business.Test.BRAFV600EK.BRAFResult.Method;
this.m_Comment = "The results are compatible with a sporadic tumor and further genetic evaluation is not indicated.";
this.m_References = YellowstonePathology.Business.Test.LynchSyndrome.LSEResult.LSEColonReferences;
}
public BRAFMutationAnalysisNotDetectedLynchSyndromeResult()
{
YellowstonePathology.Business.Test.IndicationLynchSymdrome indication = new IndicationLynchSymdrome();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Interpretation = "The BRAF V600E status was tested on this colon tumor to rule out Lynch syndrome. Immunohistochemistry for MLH1 " +
"and PMS2 showed loss of these proteins in the colon tumor. This can be either due to sporadic MLH1 methylation in the tumor or be related to a mutation in " +
"MLH1 associated with Lynch syndrome. BRAF mutations are highly correlated with sporadic MLH1 methylation and have not been seen in Lynch associated colon " +
"cancers. Therefore, the BRAF gene in the tumor was tested. The result is negative for BRAF V600E mutation in the tumor. The tumor should be tested for MLH1 " +
"methylation to rule out Lynch syndrome.";
this.m_Method = YellowstonePathology.Business.Test.BRAFMutationAnalysis.BRAFMutationAnalysisResult.Method;
this.m_Comment = "Recommend testing for MLH1 methylation.";
this.m_References = YellowstonePathology.Business.Test.LynchSyndrome.LSERule.LSEColonReferences;
}
public BRAFV600EKNotDetectedLynchSyndromeResult()
{
YellowstonePathology.Business.Test.IndicationLynchSymdrome indication = new IndicationLynchSymdrome();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Interpretation = "The BRAF V600E status was tested on this colon tumor to rule out Lynch syndrome. Immunohistochemistry for MLH1 " +
"and PMS2 showed loss of these proteins in the colon tumor. This can be either due to sporadic MLH1 methylation in the tumor or be related to a mutation in " +
"MLH1 associated with Lynch syndrome. BRAF mutations are highly correlated with sporadic MLH1 methylation and have not been seen in Lynch associated colon " +
"cancers. Therefore, the BRAF gene in the tumor was tested. The result is negative for BRAF V600E mutation in the tumor. The tumor should be tested for MLH1 " +
"methylation to rule out Lynch syndrome.";
this.m_Method = YellowstonePathology.Business.Test.BRAFV600EK.BRAFResult.Method;
this.m_Comment = "Recommend testing for MLH1 methylation.";
this.m_References = YellowstonePathology.Business.Test.LynchSyndrome.LSEResult.LSEColonReferences;
}
